DEA Extends Temporary Status of Benzimidazole-Opioids in Schedule I, Proposes Permanent Listings
The Drug Enforcement Administration is extending for one more year the temporary listing of three synthetic benzimidazole-opioid substances -- butonitazene, flunitazene and metodesnitazene -- in Schedule I of the Controlled Substances Act, it said in a notice released April 10.…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
The synthetic benzimidazole-opioids, first temporarily listed in 2022 (see 2204110029), will now remain listed in Schedule I until April 12, 2025. DEA also released a proposed rule to permanently list these synthetic benzimidazole-opioids in Schedule I, with comments due May 13. Substances may be temporarily listed under the CSA for three years.